For the quarter ending 2026-03-31, SER has $27,299K in assets. $9,671K in debts. $24,526K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 24,526 | 3,056 | 8,620 | 6,041 |
| Prepaid expenses and other current assets | 1,948 | 3,024 | 2,877 | 1,950 |
| Total current assets | 26,474 | 6,080 | 11,497 | 7,991 |
| Property and equipment, net | 472 | 465 | 580 | 588 |
| Right of use assets - operating leases | 328 | 377 | 312 | 362 |
| Right of use assets - finance leases | - | 0 | 0 | 0 |
| Other long-term prepaid assets | 25 | 29 | 24 | - |
| Total assets | 27,299 | 6,951 | 12,413 | 8,941 |
| Accounts payable | 2,827 | 1,931 | 2,731 | 1,706 |
| Accrued expenses | 1,510 | 1,207 | 1,144 | 1,310 |
| Warrant liability | 0 | 88 | 1,676 | - |
| Convertible note, net | - | - | 2,888 | - |
| Tranche liability | 1,547 | - | - | - |
| Other current liabilities | 456 | 337 | 350 | 545 |
| Total current liabilities | 6,340 | 3,563 | 8,789 | 3,561 |
| Warrant liability, non-current | 162 | 283 | 1,882 | - |
| Convertible note, net | 3,010 | 2,946 | - | - |
| Operating lease liabilities, net of current portion | 159 | 196 | 148 | 185 |
| Warrant liability | - | - | - | 3,549 |
| Total liabilities | 9,671 | 6,988 | 10,819 | 7,295 |
| Series a convertible preferred stock, 0.0001 par value, 5,000 shares authorized 965 issued and outstanding at march31, 2026 and december31, 2025 liquidation preference of 5,000 at march31, 2026 and december31, 2025 | 4,940 | 4,940 | 4,940 | 4,940 |
| Common stock, 0.0001 par value, 40,000 shares authorized and 14,899 and 10,767 shares issued and outstanding at march31, 2026 and december31, 2025, respectively | 1 | 1 | 1 | 1 |
| Additional paid-in capital | 83,093 | 58,536 | 56,987 | 52,440 |
| Accumulated other comprehensive loss | -8 | -14 | -4 | - |
| Accumulated deficit | -70,398 | -63,500 | -60,164 | -55,579 |
| Total serina therapeutics, inc. stockholders (deficit) equity | - | -37 | 1,760 | 1,802 |
| Noncontrolling deficit | - | 0 | -166 | -156 |
| Total stockholders' equity (deficit) | 17,628 | -37 | 1,594 | 1,646 |
| Total liabilities and stockholders equity (deficit) | 27,299 | 6,951 | 12,413 | 8,941 |
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)